SCHEMBL1135868

SCHEMBL1135868

COC(=O)c1ccccc1-c1ccc(C=C2SC(=S)N(Cc3ccccc3)C2=O)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 1.00
ENPP2 Q13822 1/20 0.81
MEN1 O00255 5/20 0.62
MAPT P10636 5/20 0.62
KMT2A Q03164 5/20 0.62
ALDH1A1 P00352 4/20 0.62
MCL1 Q07820 3/20 0.62
RECQL P46063 3/20 0.62
POLB P06746 3/20 0.62
TDP1 Q9NUW8 3/20 0.62
NPSR1 Q6W5P4 2/20 0.62
EIF4E P06730 1/20 0.62
EIF4G1 Q04637 1/20 0.62
THRB P10828 1/20 0.62
LMNA P02545 2/20 0.62
ALOX12 P18054 2/20 0.62
MAP3K5 Q99683 7/20 0.60
TNFRSF1A P19438 2/20 0.60
PTPN22 Q9Y2R2 2/20 0.58
PKM P14618 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1135867 1.00 SYK (1.00) SYKENPP2MEN1MAPTKMT2A
SCHEMBL12668370 1.00 SYK (1.00) SYKENPP2MEN1MAPTKMT2A
SCHEMBL30774050 1.00 SYK (1.00) SYKENPP2MEN1MAPTKMT2A
SCHEMBL4891702 0.94 SYK (0.88) SYKENPP2MEN1MAPTKMT2A
SCHEMBL4891697 0.94 SYK (0.88) SYKENPP2MEN1MAPTKMT2A
SCHEMBL4402019 0.90 ENPP2 (1.00) SYKENPP2MEN1MAPTKMT2A
SCHEMBL4398637 0.90 ENPP2 (1.00) SYKENPP2MEN1MAPTKMT2A
SCHEMBL23171552 0.85 SYK (0.75) SYKENPP2MEN1MAPTKMT2A
SCHEMBL8337281 0.85 ENPP2 (0.78) SYKENPP2MEN1MAPTKMT2A
SCHEMBL6742616 0.85 SYK (0.75) SYKENPP2MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP claimed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US claimed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP claimed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO claimed
US-9504676-B2 Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-11-29 US disclosed
US-9504676-B2 Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-11-29 US disclosed
EP-2285366-B1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NAT RECH SCIENT (FR) 2015-02-25 EP disclosed
US-20140179679-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-06-26 US disclosed
US-20140179679-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-06-26 US disclosed
US-20110112098-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-12 US disclosed
US-20110112098-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-12 US disclosed
EP-2285366-A2 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES Centre National de la Recherche Scientifique (FR) 2011-02-23 EP disclosed
EP-2285366-A2 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES Centre National de la Recherche Scientifique (FR) 2011-02-23 EP disclosed
WO-2009133294-A3 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-04-08 WO disclosed
EP-1830848-B1 USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS CELL THERAPEUTICS EUROPE SRL (IT) 2009-12-16 EP disclosed
WO-2009133294-A2 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-11-05 WO disclosed
WO-2009133294-A2 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-11-05 WO disclosed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP disclosed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN SYK 3137/4885ENPP2 2878/4885MEN1 2216/4885
US-20140179679-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES SYK, BTK, TYRO3 SYK 1/4885ENPP2 1971/4885MEN1 4288/4885
US-20110112098-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES SYK, BTK, TYRO3 SYK 1/4885ENPP2 1971/4885MEN1 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.